Specific causes of excess late mortality and association with modifiable risk factors among survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort

被引:73
作者
Dixon, Stephanie B. [1 ,2 ]
Liu, Qi [4 ]
Chow, Eric J. [5 ]
Oeffinger, Kevin C. [7 ]
Nathan, Paul C. [8 ]
Howell, Rebecca M. [9 ]
Leisenring, Wendy M. [5 ,6 ]
Ehrhardt, Matthew J. [1 ,2 ]
Ness, Kirsten K. [2 ]
Krull, Kevin R. [2 ,3 ]
Mertens, Ann C. [10 ]
Hudson, Melissa M. [1 ,2 ]
Robison, Leslie L. [2 ]
Yasui, Yutaka [2 ]
Armstrong, Gregory [1 ,2 ]
机构
[1] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA
[2] St Jude Childrens Res Hosp, Dept Epidemiol & Canc Control, Memphis, TN 38105 USA
[3] St Jude Childrens Res Hosp, Dept Psychol, Memphis, TN 38105 USA
[4] Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada
[5] Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA USA
[6] Fred Hutchinson Canc Res Ctr, Clin Stat Program, Seattle, WA USA
[7] Duke Univ, Dept Med, Durham, NC USA
[8] Univ Toronto, Hosp Sick Children, Div Hematol & Oncol, Toronto, ON, Canada
[9] Univ Texas MD Anderson Canc Ctr, Radiat Phys Dept, Houston, TX USA
[10] Emory Univ, Dept Pediat, Sch Med, Atlanta, GA USA
关键词
ACUTE LYMPHOBLASTIC-LEUKEMIA; 5-YEAR SURVIVORS; ADULT SURVIVORS; DISEASE; RECOMMENDATIONS; SURVEILLANCE;
D O I
10.1016/S0140-6736(22)02471-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background 5-year survival after childhood cancer does not fully describe life-years lost due to childhood cancer because there are a large number of deaths occurring beyond 5-years (late mortality) related to cancer and cancer treatment. Specific causes of health-related (non-recurrence, non-external) late mortality and risk reduction through modifiable lifestyle and cardiovascular risk factors are not well described. Through using a well-characterised cohort of 5-year survivors of the most common childhood cancers, we evaluated specific health-related causes of late mortality and excess deaths compared with the general US population and identified targets to reduce future risk.Methods In this multi-institutional, hospital-based, retrospective cohort study, late mortality (death >= 5 years from diagnosis) and specific causes of death were evaluated in 34 230 5-year survivors of childhood cancer diagnosed at an age younger than 21 years from 1970 to 1999 at 31 institutions in the USA and Canada; median follow-up from diagnosis was 29 years (range 5-48) in the Childhood Cancer Survivor Study. Demographic, self-reported modifiable lifestyle (ie, smoking, alcohol, physical activity, and BMI) and cardiovascular risk factors (ie, hypertension, diabetes, and dyslipidaemia) associated with health-related mortality (which excludes death from primary cancer and external causes and includes death from late effects of cancer therapy) were evaluated.Findings 40-year cumulative all-cause mortality was 23 center dot 3% (95% CI 22 center dot 7-24 center dot 0), with 3061 (51 center dot 2%) of 5916 deaths from health-related causes. Survivors 40 years or more from diagnosis experienced 131 excess health-related deaths per 10 000 person-years (95% CI 111-163), including those due to the top three causes of health-related death in the general population: cancer (absolute excess risk per 10 000 person-years 54, 95% CI 41-68), heart disease (27, 18-38), and cerebrovascular disease (10, 5-17). Healthy lifestyle and absence of hypertension and diabetes were each associated with a 20-30% reduction in health-related mortality independent of other factors (all p values <= 0 center dot 002).Interpretation Survivors of childhood cancer are at excess risk of late mortality even 40 years from diagnosis, due to many of the leading causes of death in the US population. Modifiable lifestyle and cardiovascular risk factors associated with reduced risk for late mortality should be part of future interventions.Funding US National Cancer Institute and the American Lebanese Syrian Associated Charities.Copyright (c) 2023 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1447 / 1457
页数:11
相关论文
共 47 条
  • [21] Efficacy of a Tobacco Quitline Among Adult Survivors of Childhood Cancer
    Klesges, Robert C.
    Krukowski, Rebecca A.
    Klosky, James L.
    Liu, Wei
    Srivastava, Deo Kumar
    Boyett, James M.
    Lanctot, Jennifer Q.
    Hudson, Melissa M.
    Folsom, Charla
    Robison, Leslie L.
    [J]. NICOTINE & TOBACCO RESEARCH, 2015, 17 (06) : 710 - 718
  • [22] A Worldwide Collaboration to Harmonize Guidelines for the Long-Term Follow-Up of Childhood and Young Adult Cancer Survivors: A Report From the International Late Effects of Childhood Cancer Guideline Harmonization Group
    Kremer, Leontien C. M.
    Mulder, Renee L.
    Oeffinger, Kevin C.
    Bhatia, Smita
    Landier, Wendy
    Levitt, Gill
    Constine, Louis S.
    Wallace, W. Hamish
    Caron, Huib N.
    Armenian, Saro H.
    Skinner, Roderick
    Hudson, Melissa M.
    [J]. PEDIATRIC BLOOD & CANCER, 2013, 60 (04) : 543 - 549
  • [23] Pediatric Cancer Survivorship Research: Experience of the Childhood Cancer Survivor Study
    Leisenring, Wendy M.
    Mertens, Ann C.
    Armstrong, Gregory T.
    Stovall, Marilyn A.
    Neglia, Joseph P.
    Lanctot, Jennifer Q.
    Boice, John D., Jr.
    Whitton, John A.
    Yasui, Yutaka
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (14) : 2319 - 2327
  • [24] Li YP, 2018, CIRCULATION, V138, P345, DOI [10.1161/CIRCULATIONAHA.117.032047, 10.1161/circulationaha.117.032047]
  • [25] LITTLE RJA, 2002, STAT ANAL MISSING DA, DOI DOI 10.1002/9781119013563
  • [26] Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial
    Mauz-Koerholz, Christine
    Landman-Parker, Judith
    Balwierz, Walentyna
    Ammann, Roland A.
    Anderson, Richard A.
    Attarbaschi, Andische
    Bartelt, Jorg M.
    Beishuizen, Auke
    Boudjemaa, Sabah
    Cepelova, Michaela
    Claviez, Alexander
    Daw, Stephen
    Dieckmann, Karin
    Fernandez-Teijeiro, Ana
    Fossa, Alexander
    Gattenloehner, Stefan
    Georgi, Thomas
    Hjalgrim, Lisa L.
    Hraskova, Andrea
    Karlen, Jonas
    Kluge, Regine
    Kurch, Lars
    Leblanc, Thiery
    Mann, Georg
    Montravers, Francoise
    Pears, Jean
    Pelz, Tanja
    Rajic, Vladan
    Ramsay, Alan D.
    Stoevesandt, Dietrich
    Uyttebroeck, Anne
    Vordermark, Dirk
    Koerholz, Dieter
    Hasenclever, Dirk
    Wallace, William Hamish
    [J]. LANCET ONCOLOGY, 2022, 23 (01) : 125 - 137
  • [27] Cause-specific late mortality among 5-year survivors of childhood cancer: The childhood cancer survivor study
    Mertens, Ann C.
    Liu, Qi
    Neglia, Joseph P.
    Wasilewski, Karen
    Leisenring, Wendy
    Armstrong, Gregory T.
    Robison, Leslie L.
    Yasui, Yutaka
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (19): : 1368 - 1379
  • [28] Mortality risk among 5-year survivors of childhood cancer in Germany-Results from the CVSS study (Cardiac and Vascular late Sequelae in long-term Survivors of childhood cancer study)
    Merzenich, Hiltrud
    Baaken, Dan
    Schneider, Astrid
    Neu, Marie A.
    Wingerter, Arthur
    Faber, Joerg
    Wild, Philipp S.
    Spix, Claudia
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (01) : 67 - 72
  • [29] Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation
    Metzger, Monika L.
    Link, Michael P.
    Billett, Amy L.
    Flerlage, Jamie
    Lucas, John T., Jr.
    Mandrell, Belinda N.
    Ehrhardt, Matthew J.
    Bhakta, Nickhill
    Yock, Torunn, I
    Friedmann, Alison M.
    de Alarcon, Pedro
    Luna-Fineman, Sandra
    Larsen, Eric
    Kaste, Sue C.
    Shulkin, Barry
    Lu, Zhaohua
    Li, Chen
    Hiniker, Susan M.
    Donaldson, Sarah S.
    Hudson, Melissa M.
    Krasin, Matthew J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (20) : 2276 - +
  • [30] Möller TR, 2001, J CLIN ONCOL, V19, P3173